Management Committee

H. Thomas Watkins

President and Chief Executive Officer

H. Thomas Watkins joined HGS as Chief Executive Officer and a Director of the Company in November 2004, and in December 2005 added the title of President. Mr. Watkins came to HGS with nearly twenty years of experience at Abbott Laboratories and its affiliates in the U.S. and Asia. From 1998 to 2004, he served as President of TAP Pharmaceutical Products Inc., which is jointly owned by Abbott Laboratories and Takeda Pharmaceutical Company Limited. Mr. Watkins joined Abbott in 1985 and held various executive positions in the Pharmaceutical Products Division, Diagnostics Division and HealthSystems Division prior to joining TAP in 1998. He was elected a corporate officer of Abbott in December 1996, while serving as Vice President, Diagnostic Operations, Asia and Pacific. Mr. Watkins holds a bachelor’s degree from The College of William and Mary, and a master’s degree in business administration from the University of Chicago Graduate School of Business. He is a member of the Board of Directors of Vanda Pharmaceuticals, Inc. and the U.S. Chamber of Commerce, and a member of the Health Section Governing Body of the Biotechnology Industry Organization (BIO). Mr. Watkins serves as a Trustee of The College of William and Mary Foundation and as a member of the Foundation Board of Trustees of The Mason School of Business of The College of William and Mary. He is a member of the Board of Visitors of the University of Maryland Biotechnology Institute. Mr. Watkins also currently serves as Chair of the Life Sciences Advisory Board of the State of Maryland.

James H. Davis, Ph.D., J.D.

Executive Vice President, General Counsel and Secretary

James H. Davis joined HGS as Senior Vice President, General Counsel and Secretary in May 1997. In December 2003, Dr. Davis was promoted to Executive Vice President. Prior to joining HGS, Dr. Davis was with the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P., where his practice focused on providing an integrated analysis of legal issues affecting the commercialization of new technologies, including intellectual property rights, regulatory compliance and licensing. Prior to joining Finnegan, Henderson in 1995, Dr. Davis served as General Counsel, Vice President of Research and Development, and a Director of Crop Genetics International Corporation, which he had joined in 1988 as General Counsel and Vice President of Development and Regulatory Affairs. Earlier in his career, Dr. Davis was a Partner with Weil, Gotshal & Manges, which he joined in 1986, with a practice principally concentrated on counseling and litigation relating to environmental, health, food, drug and cosmetic issues. From 1983 to 1985, he served with the U.S. Environmental Protection Agency. Dr. Davis holds a doctorate degree in Organic and Theoretical Chemistry from the California Institute of Technology, a law degree from the University of Virginia, and his Bachelor of Science and Master of Science in Chemistry degrees from Yale University. Dr. Davis serves on the Board of Directors of the Leukemia and Lymphoma Society. 

Barry A. Labinger

Executive Vice President and Chief Commercial Officer

Barry A. Labinger joined HGS in August 2005 as Executive Vice President and Chief Commercial Officer. Mr. Labinger has more than 15 years of experience in the biopharmaceutical industry, including leadership of launches and marketing of a number of successful products in a variety of therapeutic areas. Mr. Labinger was most recently with 3M Pharmaceuticals, where he served as Division Vice President. 3M Pharmaceuticals is a global division of 3M Company with marketed products in dermatology, women’s health, and cardiac therapy, along with a pipeline of immune response modifiers for the treatment of viral infections and cancers. From 2000 to 2002, Mr. Labinger was Senior Vice President and General Manager, Commercial Operations, at Immunex Corporation where he led both the Enbrel and Specialty Therapeutics franchise teams and had direct responsibility for the sales and marketing organizations. Mr. Labinger also served as Senior Director of Diabetes Marketing and Director of Glucophage Marketing at Bristol-Myers Squibb. Mr. Labinger began his pharmaceutical career at Abbott Laboratories, where he was involved in the commercialization of products for gastrointestinal and infectious diseases. Mr. Labinger earned a Master of Business Administration degree from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Arts in economics from Northwestern University.

David C. Stump, M.D.

Executive Vice President, Research and Development

David C. Stump joined the Company in November 1999 as Senior Vice President, Drug Development. In December 2003, he was promoted to Executive Vice President. Dr. Stump came to HGS from Genentech, Inc., where he was Vice President, Clinical Research, since 1995. In 1996 he was named a Genentech Fellow, only the second in Genentech’s history. Dr. Stump also served as a member of the Genentech Product Development Committee and chaired the Clinical Review Committee. While he was closely involved with overall clinical development efforts during his last five years at Genentech, Dr. Stump was most widely recognized for a decade of leadership of the company’s thrombolytic therapy drug development program, which accomplished multiple successful clinical trials and drug approvals for patients with acute myocardial infarction and acute ischemic stroke. Dr. Stump joined Genentech in 1989 from the University of Vermont where he was Associate Professor of Medicine and Biochemistry. He holds an A.B. from Earlham College and an M.D. from Indiana University. Dr. Stump received residency and fellowship training in internal medicine, hematology and oncology at the University of Iowa, where he also received advanced research training in biochemistry. In addition, he completed specialized training in hemostasis research as a visiting investigator at the University of Leuven, Belgium. Dr. Stump is certified by the American Board of Medicine, including its Medical Oncology and Hematology Subspecialty Boards. He holds membership in a variety of professional organizations and is an elected Fellow of the American College of Physicians and of the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. Dr. Stump is a member of the Board of Trustees of Adventist HealthCare and the Board of Directors of Sunesis Pharmaceuticals Inc.

Timothy Barabe

Senior Vice President and Chief Financial Officer

Mr. Barabe joined HGS in July 2006. He has held a broad range of financial and strategic roles in the life sciences and healthcare industries. From September 2005 to June 2006, Mr. Barabe was Managing Director of the U.K. for Regent Medical Ltd., a U.K.-based privately owned surgical supply company, having been its Chief Financial Officer from 2004 to September 2005. Prior to joining Regent, Mr. Barabe was with Novartis AG from 1982-2004 in a succession of senior executive positions in finance, general management, and strategic planning, including Chief Financial Officer of the Sandoz Generics Business Unit (Vienna, Austria), President of the CIBA Vision Corporation Specialty Lens Business Franchise, Group Vice President and Chief Financial Officer of CIBA Vision Corporation, and Director of Corporate Finance, Ciba-Geigy Corporation (subsequently acquired by Novartis AG). Mr. Barabe received his MBA in Finance from the University of Chicago and his BBA in Finance from the University of Massachusetts. He is a member of the Board of Directors of ArQule, Inc.

Susan Bateson

Senior Vice President, Human Resources

Susan Bateson joined HGS as Vice President, Human Resources in January 1997. In December 2000, Ms. Bateson was promoted to Senior Vice President. Prior to joining HGS, Ms. Bateson served as Director of Human Resources and Administration at the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. in Washington, D.C. Prior to joining Finnegan, Henderson in 1994, Ms. Bateson was employed by J.P. Morgan & Co. Incorporated, where she served in various leadership roles within Human Resources in the company's New York, Delaware, and London offices. Earlier in her career, Ms. Bateson held various human resources positions with Citicorp and was a financial analyst at Bankers Trust. Ms. Bateson earned her MBA in International Management from New York University's Stern School of Business and her B.A. cum laude in Economics from Mount Holyoke College. Ms. Bateson currently serves on the Board of Trustees of Mount Holyoke College, where she chairs the Audit Committee, and on the Board of Advisors of The Universities at Shady Grove, Rockville, Maryland.

Curran M. Simpson

Senior Vice President, Operations

Curran M. Simpson joined HGS in March 2003 as Vice President, Manufacturing Operations. He was promoted to Senior Vice President, Operations, in December 2005. Prior to joining HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen's North Carolina facility. In this role, he led the technology transfer, start-up and validation activities for Biogen's large-scale manufacturing facility, and completed a successful pre-approval inspection (PAI) resulting in commercialization of Amevive. Previous to his position with Biogen, Mr. Simpson held process development and manufacturing positions with several biotechnology companies, including Genencor, Genentech, Novo-Nordisk (U.S. and Europe) and Covance. Mr. Simpson has been involved in the scale-up and manufacturing operations for a number of commercial products, including Pulmozyme, TNKase, Herceptin and Retavase. Mr. Simpson earned his M.S. degree in Surface and Colloid Science (Physical Chemistry) from Clarkson University, and his B.S. degree in Chemical Engineering/Chemistry from the Clarkson College of Technology.

Other HGS Officers

Sally D. Bolmer, Ph.D.

Senior Vice President, Development and Regulatory Affairs

Sally D. Bolmer joined HGS in February 2000 as Vice President, Regulatory Affairs. In December 2002, Dr. Bolmer was promoted to Senior Vice President. She joined HGS from Centocor, Inc., where she held several positions, most recently Executive Director, Worldwide Regulatory Affairs. In that position, Dr. Bolmer had overall responsibility for developing and implementing Centocor's worldwide regulatory strategies for cardiovascular products. These responsibilities included overseeing the preclinical, clinical and manufacturing submissions for investigational new drugs and product licensing applications for biological and gene therapy products as well as preparation and maintenance of submissions for single- and multi-product facilities. Dr. Bolmer joined Centocor from Mount Sinai Medical Center, New York City, where she was Assistant Research Professor of Pathology. Previously, she was a Post-Doctoral Associate at Massachusetts Institute of Technology. Dr. Bolmer earned a Ph.D., in Biological Chemistry from Pennsylvania State University, and an Sc.B., in Biochemistry from Brown University. Dr. Bolmer is a member of the Regulatory Affairs Professional Society.

William W. Freimuth, M.D., Ph.D.

Vice President, Clinical Research — Immunology, Rheumatology and Infectious Diseases

William W. Freimuth joined HGS in August 2000 as Director of Clinical Research, Immunology and Infectious Diseases. In December 2003, he was promoted to Vice President, Clinical Research – Immunology, Rheumatology and Infectious Diseases. Before coming to HGS, Dr. Freimuth was with Pharmacia & Upjohn, most recently serving as Therapeutic Area Clinical Director – Antiviral. He joined the Phase 1/2 clinical research unit of Upjohn in 1992 and during his tenure at Pharmacia & Upjohn held a number of clinical research management positions, including responsibility for worldwide clinical development of four antiviral agents. From 1986-1992, Dr. Freimuth completed his Residency in Internal Medicine and his Rheumatology fellowship training at the University of Michigan Medical Center in Ann Arbor. Dr. Freimuth earned his M.D. from the State University of New York at Buffalo (SUNYAB) School of Medicine, where he subsequently did postdoctoral research in immunology and immunogenetics. Dr. Freimuth received his Ph.D. in Immunology from Michigan State University, and his B.S. in microbiology from the University of Michigan.

Gilles Gallant, B.Pharm, Ph.D.

Vice President, Clinical Research — Oncology

Gilles Gallant joined HGS in June 2002 as Vice President, Clinical Research – Oncology. Prior to joining HGS, Dr. Gallant was Director of Clinical Oncology at Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Gallant joined Bristol-Myers Squibb in 1991 and advanced through a succession of research management positions. He played a key role in designing and directing registrational and non-registrational clinical trials of Bristol-Myers Squibb’s oncology products in the United States, Europe and Canada. Dr. Gallant received his doctorate in medicinal chemistry and bachelor’s degree in pharmacy from the Université de Montreal in Montréal, Canada. He has co-authored numerous scientific abstracts and peer-reviewed publications in the oncology research field, and is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research.

Randy Maddux

Vice President, Manufacturing Operations

Randy Maddux joined HGS in March 2004 as Vice President of Quality. He was named Vice President, Manufacturing Operations, in December 2005. Prior to joining HGS, Mr. Maddux was Director of Quality at the Research Triangle Park, NC campus of Biogen Idec. In his eight years at Biogen, he established Biogen’s quality control function, including the development of systems and monitoring programs. He also led preparation activities for the commercial licensing of Biogen's Large Scale Manufacturing facility. Prior to his position with Biogen, Mr. Maddux served in a number of roles of increasing responsibility at Glaxo Wellcome at Research Triangle Park, including Supervisor of Clinical QA/QC, Group Leader of Methods Development and Automation, and Assistant Director of R&D Operations. Mr. Maddux earned a BS in Chemistry from East Carolina University and an MBA from Duke University, Fuqua School of Business.

Joseph A. Morin

Vice President, Engineering

Joseph (Joe) A. Morin joined HGS in 1997 as Senior Director of Capital Projects and Facilities. He was promoted to Vice President of Capital Projects, Facilities, and Engineering in October 2002. Prior to joining HGS, Mr. Morin served in a succession of project engineering roles of increasing responsibility at Celltech Biologics, now Lonza Biologics. While at Celltech, Mr. Morin was responsible for engineering, procurement, and construction management, from initial concept through to installation qualification, for large and small capital projects, including the initial construction and ultimate qualification of the Company’s biologics manufacturing facility. Mr. Morin began his career in construction and then as an engineer with Appledore Engineering, Inc., where he worked on large civil, structural and marine projects. Mr. Morin received his bachelor of science in industrial technology at the University System of New Hampshire’s Keene State College.

Daniel J. Odenheimer, Ph.D.

Vice President, Clinical Research — General Medicine

Daniel Odenheimer joined the HGS drug development team in 1998. In 2003, he was promoted to Vice President, Clinical Research - General Medicine. Dr. Odenheimer's responsibilities include developing clinical plans for new products, designing clinical trials, and recruiting and monitoring clinical trial investigators for clinical trials. Prior to joining HGS, Dr. Odenheimer worked at British Biotech Inc., where he was Director, U.S. Clinical Research. Among his responsibilities were directing the U.S. clinical development of marimastat in lung cancer and non-oncology indications. Previously, Dr. Odenheimer worked at Boehringer Mannheim Corporation's Therapeutics division. During his eight years there, he advanced through a series of positions, including Director, Department of Clinical Research. Dr. Odenheimer earned a Ph.D. in Epidemiology and an M.S. degree in Biostatistics at the University of Michigan. He earned an M.S. in Epidemiology and a B.S. in Genetics from the University of California, Berkeley.

Jerry Parrott

Vice President, Corporate Communications and Public Policy

Jerry Parrott joined HGS in July 2001 as Vice President, Corporate Communications and Public Policy. As Principal of Policy Advocates, Inc., from 1995-2001, Mr. Parrott’s clients included HGS, Bristol-Myers Squibb, Ciba-Geigy, Diversa, Genentech, HealthCare Ventures, Hoffmann-La Roche, Western Digital, Wyeth and other companies. He previously held senior policy and corporate communications management positions with Bristol-Myers Squibb Company (1979-1995), American Hospital Supply Corporation (1976-1979), and Walgreen Company (1973-1976). Mr. Parrott helped launch several important therapeutic products, including: Zenapax, the first genetically engineered drug to reduce risk of organ rejection; VIDEX, the second anti-AIDS drug; Taxol, the breakthrough cancer drug; Nuprin, the first nonprescription ibuprofen; and Comtrex, the nonprescription cough-cold medicine. He received his B.A. from the University of South Florida and attended graduate school as a University Fellow at Northwestern University. Mr. Parrott is Chair of the Board of Directors of Maryland Health Care Product Development Corporation, and a member of the Executive Committee and Board of Directors of MdBio and the Technology Council of Maryland.

Sarah Thomas

Vice President, Quality

Sarah Thomas joined HGS in 2003 as Director of Quality Assurance. She was promoted to Vice President, Quality in 2007. In her current position she is responsible for the Quality Assurance and Quality Control functions at HGS. Prior to joining HGS, Ms. Thomas held positions in Quality Assurance with increasing levels of responsibility at several biotechnology and pharmaceutical firms including Cell Genesys, Alza Corporation, Sequus Pharmaceuticals, Syntex and Adria-SP. In her career she has worked with products at various stages of clinical and commercial development, guiding Quality programs through the transition from clinical to commercial manufacturing, including Pre-Approval Inspection and commercial launch. Ms. Thomas earned an M.B.A. from George Washington University and a B.S. in Chemistry from Butler University.

Michele M. Wales, Ph.D., J.D.

Vice President, Intellectual Property

Michele M. Wales joined the HGS Intellectual Property department in 1998, and was promoted to Vice President, Intellectual Property, in 2007. Prior to HGS, Dr. Wales was with the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., where she began her legal career in 1995. Dr. Wales earned her Ph.D. in human genetics and molecular biology from The Johns Hopkins Medical School, where she did post-doctoral work in the Department of Oncology. She earned her J.D. from George Washington University National Law Center, and her B.S. cum laude in molecular and cellular biology from the University of Connecticut. While at Johns Hopkins, Dr. Wales co-discovered and characterized the novel tumor suppressor gene, HIC-1, which is associated with the development of a number of cancers and for which patents have been granted.

Ann L. Wang

Vice President, Clinical Operations

Ann L. Wang joined HGS as Director of Clinical Operations in December 2000. She was promoted to Vice President, Clinical Operations in December 2003. Prior to HGS, Ms. Wang was Director of Clinical Operations for Pharmaceutical Research Associates International (PRA), a contract research organization where she was responsible for directing delivery of clinical trials services to PRA clients. From 1988-1998, Ms. Wang advanced through a series of clinical operations positions of increasing responsibility at Centocor, Inc., ultimately serving as Associate Director, Clinical Operations and Administration. While at Centocor, she led implementation of the program leading to worldwide approval of the recombinant antiplatelet drug, ReoPro. Ms. Wang began her career in as a bench scientist, first at the Lombardi Cancer Research Center of Georgetown University and then at SmithKline & French, where she was responsible for establishing a Molecular Oncology laboratory. Ms. Wang earned her B.A. in Organismal Biology at The Johns Hopkins University and did postgraduate work at Georgetown University in physiology.